Nature communications · 2023
Somatically hypermutated antibodies isolated from SARS-CoV-2 Delta infected patients cross-neutralize heterologous variants.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yu Haisheng, Liu Banghui, Zhang Yudi, Gao Xijie, Wang Qian, Xiang Haitao, Peng Xiaofang, Xie Caixia, Wang Yaping, Hu Peiyu, Shi Jingrong, Shi Quan, Zheng Pingqian, Feng Chengqian, Tang Guofang, Liu Xiaopan, Guo Liliangzi, Lin Xiumei, Li Jiaojiao, Liu Chuanyu, Huang Yaling, Yang Naibo, Chen Qiuluan, Li Zimu, Su Mengzhen, Yan Qihong, Pei Rongjuan, Chen Xinwen, Liu Longqi, Hu Fengyu, Liang Dan, Ke Bixia, Ke Changwen, Li Feng, He Jun, Wang Meiniang, Chen Ling, Xiong Xiaoli, Tang Xiaoping
Аннотация
SARS-CoV-2 Omicron variants feature highly mutated spike proteins with extraordinary abilities in evading antibodies isolated earlier in the pandemic. Investigation of memory B cells from patients primarily with breakthrough infections with the Delta variant enables isolation of a number of neutralizing antibodies cross-reactive to heterologous variants of concern (VOCs) including Omicron variants (BA.1-BA.4). Structural studies identify altered complementarity determining region (CDR) amino acids and highly unusual heavy chain CDR2 insertions respectively in two representative cross-neutralizing antibodies-YB9-258 and YB13-292. These features are putatively introduced by somatic hypermutation and they are heavily involved in epitope recognition to broaden neutralization breadth. Previously, insertions/deletions were rarely reported for antiviral antibodies except for those induced by HIV-1 chronic infections. These data provide molecular mechanisms for cross-neutralization of heterologous SARS-CoV-2 variants by antibodies isolated from Delta variant infected patients with implications for future vaccination strategy.